EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update

Annals of the Rheumatic Diseases

Volumn 76, Issue 1, 2016, Pages 17-28

  Agca, R ^a   Heslinga, S C ^a   Rollefstad, S ^b   Heslinga, M ^a   McInnes, I B ^c   Peters, M J L ^a   Kvien, T K ^b   Dougados, M ^d   Radner, H ^e   Atzeni, F ^f   Primdahl, J ^g,h,i   Sodergren A ^j   Wallberg Jonsson, S ^j   Van Rompay, J ^k   Zabalan, C ^l   Pedersen, T R ^m   Jacobsson, L ^n,o   De Vlam, K ^p   Gonzalez Gay, M A ^q   Semb, A G ^b   Kitas, G D ^r   Smulders, Y M ^a   Szekanecz, Z ^s   Sattar, N ^c   Symmons, D P M ^r   Nurmohamed, M T ^a   more..

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b DIAKONHJEMMET HOSPITAL   (Norway)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d VU University Medical Center ^*  (France)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^g UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^h Hospital of Southern Jutland   (Denmark)

ⁱ King Christian the Xth Hospital   (Denmark)

^j UMEÅ UNIVERSITY   (Sweden)

^k PARE (Patient Research Partners)   (Belgium)

^l Romanian League Against Rheumatism   (Romania)

^m UNIVERSITY OF OSLO   (Norway)

ⁿ UNIVERSITY OF GOTHENBURG   (Sweden)

^o LUND UNIVERSITY   (Sweden)

^p UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^q UNIVERSITY OF CANTABRIA   (Spain)

^r UNIVERSITY OF MANCHESTER   (United Kingdom)

^s UNIVERSITY OF DEBRECEN   (Hungary)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEFLUNOMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT;

ANKYLOSING SPONDYLITIS; ARTHROPATHY; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOLOGIST; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; DRUG EFFICACY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATORY JOINT DISORDER; PRACTICE GUIDELINE; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RHEUMATOLOGIST; RISK MANAGEMENT; COMPLICATION; CONSENSUS DEVELOPMENT; DIRECTIVE COUNSELING; LIFESTYLE; PHYSICIAN ATTITUDE; PROCEDURES; RHEUMATOLOGY; RISK ASSESSMENT; RISK FACTOR;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; DIRECTIVE COUNSELING; HUMANS; LIFE STYLE; PHYSICIAN'S ROLE; RHEUMATOLOGY; RISK ASSESSMENT; RISK FACTORS; RISK MANAGEMENT; SPONDYLITIS, ANKYLOSING;

EID: 84991585385     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-209775     Document Type: Article

References (164)

1. van Halm V.P., Peters MJL, Voskuyl AE, et al Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 2009; 68:1395-400.
2. Lindhardsen J, Ahlehoff O, Gislason G.H., et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 2011; 70:929-34.
3. Hippisley-Cox J., Coupland C, Vinogradova Y., et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008; 336:1475-82.
4. Peters MJ, Symmons DP, McCarey D, et al EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69:325-31.
5. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117:743-53.
6. Conroy RM, Pyorala K, Fitzgerald A.P., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24:987-1003.
7. Piepoli MF, Hoes AW, Agewall S, et al 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37:2315-81.
8. Arts EE, Popa C, den Broeder AA, et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis 2015; 74:668-74.
9. Gómez-Vaquero C., Corrales A, Zacarias A., et al. SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis. Arthritis Res Ther 2013; 15:R91.
10. van der Heijde D, Aletaha D, Carmona L, et al. 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis 2015; 74:8-13.
11. Guyatt GH, Oxman AD, Vist G.E., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924-6.
12. Dadoun S, Zeboulon-Ktorza N, Combescure C., et al. Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. Joint Bone Spine 2013; 80:29-33.
13. Humphreys JH, Warner A, Chipping J., et al. Mortality trends in patients with early rheumatoid arthritis over 20 years: results from the Norfolk Arthritis Register. Arthritis Care Res (Hoboken) 2014; 66:1296-301.
14. Liao KP, Solomon DH Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford) 2013; 52:45-52.
15. Solomon DH, Kremer J, Curtis J.R., et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010; 69:1920-5.
16. Bakland G, Gran JT, Nossent JC Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 2011; 70:1921-5.
17. Mok CC, Kwok CL, Ho L.Y., et al. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum 2011; 63:1182-9.
18. Exarchou S, Lie E, Lindström U, et al. Mortality in ankylosing spondylitis: results from a nationwide population-based study. Ann Rheum Dis 2016; 75:1466-72.
19. Bremander A, Petersson IF, Bergman S, et al Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res (Hoboken) 2011; 63:550-6.
20. Zöller B., Li X, Sundquist J., et al. Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. BMC Neurol 2012; 12:41.
21. Brophy S, Cooksey R, Atkinson M., et al. No increased rate of acute myocardial infarction or stroke among patients with ankylosing spondylitis: a retrospective cohort study using routine data. Semin Arthritis Rheum 2012; 42:140-5.
22. Chou CH, Lin MC, Peng C.L., et al. A nationwide population-based retrospective cohort study: increased risk of acute coronary syndrome in patients with ankylosing spondylitis. Scand J Rheumatol 2014; 43:132-6.
23. Essers I, Stolwijk C, Boonen A., et al. Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study. Ann Rheum Dis 2016; 75:203-9.
24. Haroon NN, Paterson JM, Li P, et al Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. Ann Intern Med 2015; 163:409-16.
25. Keller JJ, Hsu JL, Lin S.M., et al. Increased risk of stroke among patients with ankylosing spondylitis: a population-based matched-cohort study. Rheumatol Int 2014; 34:255-63.
26. Mathieu S, Pereira B, Soubrier M. Cardiovascular events in ankylosing spondylitis: an updated meta-analysis. Semin Arthritis Rheum 2015; 44:551-5.
27. Peters MJ, Visman I, Nielen M.M., et al. Ankylosing spondylitis: a risk factor for myocardial infarction? Ann Rheum Dis 2010; 69:579-81.
28. Kang JH, Chen YH, Lin HC Comorbidity profiles among patients with ankylosing spondylitis: a nationwide population-based study. Ann Rheum Dis 2010; 69:1165-8.
29. Peters MJ, van Eijk IC, Smulders YM, et al. Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 2010; 37:161-6.
30. Resorlu H, Akbal A, Resorlu M., et al. Epicardial adipose tissue thickness in patients with ankylosing spondylitis. Clin Rheumatol 2015; 34:295-9.
31. Gonzalez-Juanatey C., Vazquez-Rodriguez TR, Miranda-Filloy JA, et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore) 2009; 88:358-65.
32. Dik VK, Peters MJ, Dijkmans P.A., et al. The relationship between disease-related characteristics and conduction disturbances in ankylosing spondylitis. Scand J Rheumatol 2010; 39:38-41.
33. Forsblad-d'Elia H, Wallberg H, Klingberg E, et al. Cardiac conduction system abnormalities in ankylosing spondylitis: a cross-sectional study. BMC Musculoskelet Disord 2013; 14:237.
34. Horreau C, Pouplard C, Brenaut E., et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol 2013; 27(Suppl 3):12-29.
35. Buckley C, Cavill C, Taylor G., et al. Mortality in psoriatic arthritis - a single-center study from the UK. J Rheumatol 2010; 37:2141-4.
36. Ogdie A, Yu Y, Haynes K., et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 2015; 74:326-32.
37. Gladman DD, Ang M, Su L., et al. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009; 68:1131-5.
38. Ernste FC, Sánchez-Menéndez M, Wilton KM, et al. Cardiovascular risk profile at the onset of psoriatic arthritis: a population-based cohort study. Arthritis Care Res (Hoboken) 2015; 67:1015-21.
39. Gulati AM, Semb AG, Rollefstad S, et al On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trondelag Health Study. Ann Rheum Dis 2016; 75:819-24.
40. Edson-Heredia E., Zhu B, Lefevre C., et al. Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink. J Eur Acad Dermatol Venereol 2015; 29:955-63.
41. Shang Q, Tam LS, Sanderson J.E., et al. Increase in ventricular-arterial stiffness in patients with psoriatic arthritis. Rheumatology (Oxford) 2012; 51:2215-23.
42. Costa L, Caso F, D'Elia L, et al. Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol 2012; 31:711-15.
43. Angel K, Provan SA, Gulseth H.L., et al. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension 2010; 55:333-8.
44. Duru N, van der Goes MC, Jacobs JW, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2013; 72:1905-13.
45. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70:896-904.
46. Roubille C, Richer V, Starnino T., et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74:480-9.
47. del Rincón I, Battafarano DF, Restrepo JF, et al. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Ann Rheum Dis 2014; 66:264-72.
48. Lindhardsen J, Gislason GH, Jacobsen S, et al Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis 2013; Published Online First 8 June 2013.
49. Ajeganova S, Andersson ML, Frostegård J, et al. Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: a 10-year observational cohort study. J Rheumatol 2013; 40:1958-66.
50. Arts EE, Fransen J, den Broeder AA, et al. The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients. Ann Rheum Dis 2015; 74:998-1003.
51. Myasoedova E, Chandran A, Ilhan B., et al. The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease. Ann Rheum Dis 2016; 75:560-5.
52. Zhang J, Chen L, Delzell E., et al. The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis 2014; 73:1301-8.
53. Innala L, Möller B, Ljung L., et al. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther 2011; 13:R131.
54. Rao VU, Pavlov A, Klearman M., et al. An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy. Arthritis Rheumatol 2015; 67:372-80.
55. Barnabe C, Martin BJ, Ghali WA Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011; 63:522-9.
56. Bili A, Tang X, Pranesh S., et al. Tumor necrosis factor α inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014; 66:355-63.
57. Chatterjee S, Sarkate P, Ghosh S., et al. Early, structured disease modifying anti-rheumatic drug (DMARD) therapy reduces cardiovascular risk in rheumatoid arthritis - a single centre study using non-biologic drugs. J Assoc Physicians India 2013; 61:531-4.
58. Desai RJ, Rao JK, Hansen R.A., et al. Tumor necrosis factor-α inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study. J Rheumatol 2014; 41:2129-36.
59. Ljung L, Askling J, Rantapää-Dahlqvist S, et al. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study. Arthritis Res Ther 2014; 16:R127.
60. Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011; 108:1362-70.
61. Morgan CL, Emery P, Porter D., et al. Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data. Rheumatology (Oxford) 2014; 53:186-94.
62. Solomon DH, Curtis JR, Saag K.G., et al. Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs. Am J Med 2013; 126:730. e9-17.
63. Benucci M, Saviola G, Manfredi M., et al. Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis. Biologics 2013; 7:69-75.
64. Kerekes G, Soltész P, Dér H, et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol 2009; 28:705-10.
65. Kume K, Amano K, Yamada S., et al. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. J Rheumatol 2011; 38:2169-71.
66. Ajeganova S, de Faire U, Jogestrand T, et al Carotid atherosclerosis, disease measures, oxidized low-density lipoproteins, and atheroprotective natural antibodies for cardiovascular disease in early rheumatoid arthritis - an inception cohort study. J Rheumatol 2012; 39:1146-54.
67. Galarraga B, Khan F, Kumar P., et al. Etanercept improves inflammation-associated arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford) 2009; 48:1418-23.
68. Kerekes G, Soltész P, Szucs G., et al. Effects of adalimumab treatment on vascular disease associated with early rheumatoid arthritis. Isr Med Assoc J 2011; 13:147-52.
69. Ristić GG, Lepić T, Glisić B, et al. Rheumatoid arthritis is an independent risk factor for increased carotid intima-media thickness: impact of anti-inflammatory treatment. Rheumatology (Oxford) 2010; 49:1076-81.
70. Vassilopoulos D, Gravos A, Vlachopoulos C., et al. Adalimumab decreases aortic stiffness independently of its effect in disease activity in patients with rheumatoid arthritis. Clin Rheumatol 2015; 34:359-64.
71. Vizzardi E, Cavazzana I, Sciatti E., et al. Evaluation of ascending aorta wall in rheumatoid arthritis by tissue and strain Doppler imaging during anti-tumor necrosis factor-α therapy. Clin Cardiol 2014; 37:738-43.
72. Mäki-Petäjä KM, Elkhawad M, Cheriyan J, et al. Anti-tumor necrosis factor-alpha therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. Circulation 2012; 126:2473-80.
73. Myasoedova E, Crowson CS, Kremers H.M., et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011; 70:482-7.
74. van Sijl A.M., Peters MJ, Knol D.L., et al. The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis. Semin Arthritis Rheum 2011; 41:393-400.
75. Boyer JF, Bongard V, Cantagrel A., et al. Link between traditional cardiovascular risk factors and inflammation in patients with early arthritis: results from a French multicenter cohort. Arthritis Care Res (Hoboken) 2012; 64:872-80.
76. Liao KP, Cai T, Gainer V.S., et al. Lipid and lipoprotein levels and trend in rheumatoid arthritis compared to the general population. Arthritis Care Res (Hoboken) 2013; 65:2046-50.
77. Semb AG, Holme I, Kvien T.K., et al. Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial. Rheumatology (Oxford) 2011; 50:324-9.
78. Toms TE, Panoulas VF, Douglas KMJ, et al. Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis? Angiology 2011; 62:167-75.
79. de Groot L Jager NA, Westra J, et al. Does reduction of disease activity improve early markers of cardiovascular disease in newly diagnosed rheumatoid arthritis patients? Rheumatology (Oxford) 2015; 54:1257-61.
80. Filippatos TD, Derdemezis CS, Voulgari P.V., et al. Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study. Scand J Rheumatol 2013; 42:169-75.
81. Georgiadis AN, Voulgari PV, Argyropoulou M.I., et al. Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum 2008; 38:13-19.
82. Curtis JR, John A, Baser O. Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken) 2012; 64:1282-91.
83. Daïen C.I., Duny Y, Barnetche T., et al. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis 2012; 71:862-8.
84. Kerr G, Aujero M, Richards J., et al. Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications. Arthritis Care Res (Hoboken) 2014; 66:1619-26.
85. Kirkham BW, Wasko MC, Hsia E.C., et al. Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation. Ann Rheum Dis 2014; 73:161-9.
86. Liao KP, Playford MP, Frits M, et al The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am Heart Assoc 2015; 4:pii: e001588.
87. Morris SJ, Wasko MC, Antohe J.L., et al. Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2011; 63:530-4.
88. Navarro-Millán I, Charles-Schoeman C, Yang S, et al. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis Rheum 2013; 65:1430-8.
89. Rho YH, Oeser A, Chung C.P., et al. Drugs used in the treatment of rheumatoid arthritis: relationship between current use and cardiovascular risk factors. Arch Drug Inf 2009; 2:34-40.
90. Ronda N, Greco D, Adorni M., et al. New anti-atherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism. Arch Drug Inf 2015; 67: 1155-64.
91. Sandoo A, van Zanten JJCS, Toms TE, et al. Anti-TNFalpha therapy transiently improves high density lipoprotein cholesterol levels and microvascular endothelial function in patients with rheumatoid arthritis: a pilot study. BMC Musculoskelet Disord 2012; 13:127.
92. Soubrier M, Jouanel P, Mathieu S., et al. Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Joint Bone Spine 2008; 75:22-4.
93. Arts E, Fransen J, Lemmers H., et al. High-density lipoprotein cholesterol subfractions HDL2 and HDL3 are reduced in women with rheumatoid arthritis and may augment the cardiovascular risk of women with RA: a cross-sectional study. Arthritis Res Ther 2012; 14:R116.
94. McInnes IB, Thompson L, Giles J.T., et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis 2015; 74:694-702.
95. Raterman HG, Levels H, Voskuyl A.E., et al. HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab. Ann Rheum Dis 2013; 72:560-5.
96. Hsue PY, Scherzer R, Grunfeld C., et al. Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis. J Am Heart Assoc 2014; 3:e001267.
97. Makrilakis K, Fragiadaki K, Smith J., et al. Interrelated reduction of chemerin and plasminogen activator inhibitor-1 serum levels in rheumatoid arthritis after interleukin-6 receptor blockade. Clin Rheumatol 2015; 34:419-27.
98. Mathieu S, Pereira B, Dubost J.J., et al. No significant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment. Rheumatology (Oxford) 2012; 51:1107-11.
99. Navarro G, Taroumian S, Barroso N., et al. Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums. Semin Arthritis Rheum 2014; 43:458-69.
100. Souto A, Salgado E, Maneiro J.R., et al. Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol 2015; 67:117-27.
101. Strang AC, Bisoendial RJ, Kootte R.S., et al. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. Atherosclerosis 2013; 229:174-81.
102. Peters MJL, Voskuyl AE, Sattar N, et al The interplay between inflammation, lipids and cardiovascular risk in rheumatoid arthritis: why ratios may be better. Int J Clin Pract 2010; 64:1440-3.
103. Perk J, De Backer G, Gohlke H, et al European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Int J Behav Med 2012; 19:403-88.
104. Crowson CS, Matteson EL, Roger V.L., et al. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol 2012; 110:420-4.
105. Arts EE, Popa CD, den Broeder AA, et al. Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms. Ann Rheum Dis 2016; 75:674-80.
106. Corrales A, Parra JA, González-Juanatey C, et al. Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than Coronary Artery Calcification Score to detect subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 2013; 72:1764-70.
107. Hippisley-Cox J., Coupland C, Robson J., et al. Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database. BMJ 2010; 341:c6624.
108. Goodson NJ, Wiles NJ, Lunt M, et al Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002; 46:2010-19.
109. Hannawi S, Haluska B, Marwick T.H., et al. Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation. Arthritis Res Ther 2007; 9:R116.
110. Evans MR, Escalante A, Battafarano D.F., et al. Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis. Arthritis Rheum 2011; 63:1211-20.
111. del Rincón I, Freeman GL, Haas RW, et al. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum 2005; 52:3413-23.
112. Semb AG, Rollefstad S, Provan S.A., et al. Carotid plaque characteristics and disease activity in rheumatoid arthritis. J Rheumatol 2013; 40:359-68.
113. Wållberg-Jonsson S., Ohman M, Rantapää-Dahlqvist S. Which factors are related to the presence of atherosclerosis in rheumatoid arthritis? Scand J Rheumatol 2004; 33:373-9.
114. Corrales A, González-Juanatey C, Peiró ME, et al. Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. Ann Rheum Dis 2014; 73:722-7.
115. van den Berg MH, de Boer IG, le Cessie S, et al. Are patients with rheumatoid arthritis less physically active than the general population? J Clin Rheumatol 2007; 13:181-6.
116. Metsios GS, Stavropoulos-Kalinoglou A, Panoulas V.F., et al. Association of physical inactivity with increased cardiovascular risk in patients with rheumatoid arthritis. Eur J Cardiovasc Prev Rehabil 2009; 16:188-94.
117. Hernández-Hernández V, Ferraz-Amaro I, Díaz-González F. Influence of disease activity on the physical activity of rheumatoid arthritis patients. Rheumatology (Oxford) 2014; 53:722-31.
118. Metsios GS, Stavropoulos-Kalinoglou A, Veldhuijzen van Zanten JJ, et al. ndividualised exercise improves endothelial function in patients with rheumatoid arthritis. Ann Rheum Dis 2014; 73:748-51.
119. Lemmey AB, Marcora SM, Chester K, et al Effects of high-intensity resistance training in patients with rheumatoid arthritis: a randomized controlled trial. Arthritis Rheum 2009; 61:1726-34.
120. Stavropoulos-Kalinoglou A., Metsios GS, Veldhuijzen van Zanten JJ, et al. ndividualised aerobic and resistance exercise training improves cardiorespiratory fitness and reduces cardiovascular risk in patients with rheumatoid arthritis. Ann Rheum Dis 2013; 72:1819-25.
121. Ford ES. Does exercise reduce inflammation? Physical activity and C-reactive protein among U.S. adults. Epidemiology 2002; 13:561-8.
122. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013; 368:1279-90.
123. Sköldstam L., Hagfors L, Johansson G. An experimental study of a Mediterranean diet intervention for patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62:208-14.
124. Iversen MD, Hammond A, Betteridge N. Self-management of rheumatic diseases: state of the art and future perspectives. Ann Rheum Dis 2010; 69: 955-63.
125. John H, Hale ED, Treharne G.J., et al. A randomized controlled trial of a cognitive behavioural patient education intervention vs a traditional information leaflet to address the cardiovascular aspects of rheumatoid disease. Rheumatology (Oxford) 2013; 52:81-90.
126. Chung CP, Giles JT, Petri M, et al Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the multi-ethnic study of atherosclerosis. Semin Arthritis Rheum 2012; 41:535-44.
127. Protogerou AD, Panagiotakos DB, Zampeli E, et al Arterial hypertension assessed "out-of-office" in a contemporary cohort of rheumatoid arthritis patients free of cardiovascular disease is characterized by high prevalence, low awareness, poor control and increased vascular damage-associated "white coat" phenomenon. Arthritis Res Ther 2013; 15:R142.
128. Baghdadi LR, Woodman RJ, Shanahan E.M., et al. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS ONE 2015; 10:e0117952.
129. Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008; 47:72-5.
130. Kellner H, Bornholdt K, Hein G. Leflunomide in the treatment of patients with early rheumatoid arthritis - results of a prospective non-interventional study. Clin Rheumatol 2010; 29:913-20.
131. Snowden S, Nelson R. The effects of nonsteroidal anti-inflammatory drugs on blood pressure in hypertensive patients. Cardiol Rev 2011; 19:184-91.
132. Robert N, Wong GW, Wright JM Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev 2010;(1):CD007893.
133. De Vera M.A., Choi H, Abrahamowicz M., et al. Impact of statin discontinuation on mortality in patients with rheumatoid arthritis: a population-based study. Arthritis Care Res (Hoboken) 2012; 64:809-16.
134. Rollefstad S, Ikdahl E, Hisdal J., et al. Systemic inflammation in patients with inflammatory joint diseases does not influence statin dose needed to obtain LDL cholesterol goal in cardiovascular prevention. Ann Rheum Dis 2015; 74: 1544-50.
135. Semb AG, Kvien TK, DeMicco D.A., et al. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum 2012; 64:2836-46.
136. Sheng X, Murphy MJ, MacDonald T.M., et al. The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population. BMC Public Health 2012; 12:712.
137. Rollefstad S, Kvien TK, Holme I, et al Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic. Ann Rheum Dis 2013; 72:1968-74.
138. Rollefstad S, Ikdahl E, Hisdal J., et al. Rosuvastatin-induced carotid plaque regression in patients with inflammatory joint diseases: the rosuvastatin in rheumatoid arthritis, ankylosing spondylitis and other inflammatory joint diseases study. Ann Rheum Dis 2015; 67:1718-28.
139. McCarey DW, McInnes IB, Madhok R, et al Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004; 363:2015-21.
140. Cojocaru L, Rusali AC, Suta C, et al The role of simvastatin in the therapeutic approach of rheumatoid arthritis. Autoimmune Dis 2013; 2013:326258.
141. Lv S, Liu Y, Zou Z., et al. The impact of statins therapy on disease activity and inflammatory factor in patients with rheumatoid arthritis: a meta-analysis. Clin Exp Rheumatol 2015; 33:69-76.
142. Mäki-Petäjä KM, Booth AD, Hall FC, et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 2007; 50:852-8.
143. Cragg MS. The potential effect of statins on rituximab immunotherapy. PLoS Med 2008; 5:e77.
144. Winiarska M, Bil J, Wilczek E., et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med 2008; 5:e64.
145. Ennishi D, Asai H, Maeda Y., et al. Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol 2010; 21:1217-21.
146. Koo YX, Tan DS, Tan I.B., et al. Effect of concomitant statin, metformin, or aspirin on rituximab treatment for diffuse large B-cell lymphoma. Leuk Lymphoma 2011; 52:1509-16.
147. Nowakowski GS, Maurer MJ, Habermann T.M., et al. Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. J Clin Oncol 2010; 28:412-17.
148. Samaras P, Heider H, Haile S.R., et al. Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP. Ann Hematol 2010; 89:783-7.
149. Das S, Fernandez Matilla M, Dass S, et al Statins do not influence clinical response and B cell depletion after rituximab treatment in rheumatoid arthritis. Ann Rheum Dis 2013; 72:463-4.
150. Lehane PB, Lacey S, Hessey E.W., et al. Effect of concomitant statins on rituximab efficacy in patients with rheumatoid arthritis. Ann Rheum Dis 2014; 73:1906-8.
151. Mazilu D, Gudu T, Ionescu R., et al. Statins do not influence long-term rituximab clinical efficiency in rheumatoid arthritis patients. Biomed Res Int 2014; 2014:689426.
152. Arts EE, Jansen TL, Den Broeder A, et al. Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 2011; 70:877-8.
153. Pharmacovigilance Risk Assessment Committee (PRAC). New safety advice for diclofenac - CMDh endorses PRAC recommendation. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2013/06/news-detail-001830.jsp&mid=WC0b01ac058004d5c1.
154. Pharmacovigilance Risk Assessment Committee (PRAC). PRAC recommends updating advice on use of high-dose ibuprofen. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2015/04/news-detail-002306.jsp&mid=WC0b01ac058004d5c1
155. van den Berg R, Baraliakos X, Braun J, et al. First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Rheumatology (Oxford) 2012; 51:1388-96.
156. Ajeganova S, Svensson B, Hafström I. Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. BMJ Open 2014; 4:e004259.
157. Aviña-Zubieta J.A., Abrahamowicz M, De Vera MA, et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology (Oxford) 2013; 52:68-75.
158. Greenberg JD, Kremer JM, Curtis J.R., et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70:576-82.
159. Aviña-Zubieta J.A., Abrahamowicz M, Choi H.K., et al. Risk of cerebrovascular disease associated with the use of glucocorticoids in patients with incident rheumatoid arthritis: a population-based study. Ann Rheum Dis 2011; 70:990-5.
160. Nadareishvili Z, Michaud K, Hallenbeck J.M., et al. Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. Arthritis Rheum 2008; 59:1090-6.
161. van Sijl A.M., Boers M, Voskuyl A.E., et al. Confounding by indication probably distorts the relationship between steroid use and cardiovascular disease in rheumatoid arthritis: results from a prospective cohort study. PLoS ONE 2014; 9: e87965.
162. Solomon DH, Greenberg J, Curtis J.R., et al. Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a Consortium of Rheumatology Researchers of North America Registry Study. Arthritis Rheumatol 2015; 67:1995-2003.
163. Wiersma T, Smulders YM, Stehouwer C.D., et al. [Summary of the multidisciplinary guideline on cardiovascular risk management (revision 2011)]. Ned Tijdschr Geneeskd 2012; 156:A5104.
164. Ray KK, Kastelein JJ, Boekholdt S.M., et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 2014; 35:960-8.